Potential therapeutic options for COVID-19: an update on current evidence
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …
pandemic and is a major public health concern nowadays. The rapid and global spread of …
[HTML][HTML] Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
M Farahani, Z Niknam, LM Amirabad… - Biomedicine & …, 2022 - Elsevier
Deciphering the molecular downstream consequences of severe acute respiratory
syndrome coronavirus (SARS-CoV)− 2 infection is important for a greater understanding of …
syndrome coronavirus (SARS-CoV)− 2 infection is important for a greater understanding of …
[HTML][HTML] Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
L Vangeel, W Chiu, S De Jonghe, P Maes, B Slechten… - Antiviral research, 2022 - Elsevier
We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has
become the dominant infective strain. We report the structures of the Omicron spike trimer on …
become the dominant infective strain. We report the structures of the Omicron spike trimer on …
[HTML][HTML] Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA. 1 and BA. 2
C Planchais, I Fernández, T Bruel… - Journal of Experimental …, 2022 - rupress.org
Disclosures: C. Planchais reported a patent to PCT/EP2022/058777 licensed (SpikImm). I.
Fernández reported a patent to PCT/EP2022/058777 licensed (SpikImm). T. Bruel reported …
Fernández reported a patent to PCT/EP2022/058777 licensed (SpikImm). T. Bruel reported …
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
Structural insights for neutralization of Omicron variants BA. 1, BA. 2, BA. 4, and BA. 5 by a broadly neutralizing SARS-CoV-2 antibody
In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …
Innate and adaptive immunity during SARS-CoV-2 infection: biomolecular cellular markers and mechanisms
The coronavirus 2019 (COVID-19) pandemic was caused by a positive sense single-
stranded RNA (ssRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
stranded RNA (ssRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening
The main protease (Mpro) of SARS-CoV-2 is essential for viral replication and has been the
focus of many drug discovery efforts since the start of the COVID-19 pandemic. Nirmatrelvir …
focus of many drug discovery efforts since the start of the COVID-19 pandemic. Nirmatrelvir …
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
E Miguez-Rey, D Choi, S Kim, S Yoon… - Expert Opinion on …, 2022 - Taylor & Francis
ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …